Buy Biocon, Dishman and Divis Laboratories: Avinash Gorakshekar

In a chat with ET Now, Avinash Gorakshekar, Head of Research, Anagram Capital Ltd., talks about mid-cap pharmaceutical stocks.

From the mid-cap pharmaceutical lot, the excitement is still quite evident there?

Within the mid-cap pharma kind of opportunity, there are specific slots like CRAMS or typically outsourcing kind of players, which are doing well. In fact in terms of Biocon also, probably the company’s numbers have been quite encouraging. In fact even in the coming quarter, we expect that the company is going to show pretty good, decent kind of upsides. More importantly they have managed the merger of the global subsidiary, which they took over quite recently, so more importantly on a case to case basis, mid caps definitely look interesting, something like a Dishman or may be a Divis Laboratories in the CRAM space also looks quite interesting.